303 related articles for article (PubMed ID: 28823869)
1. Intermittent Glucocorticoid Dosing Improves Muscle Repair and Function in Mice with Limb-Girdle Muscular Dystrophy.
Quattrocelli M; Salamone IM; Page PG; Warner JL; Demonbreun AR; McNally EM
Am J Pathol; 2017 Nov; 187(11):2520-2535. PubMed ID: 28823869
[TBL] [Abstract][Full Text] [Related]
2. Intermittent glucocorticoid steroid dosing enhances muscle repair without eliciting muscle atrophy.
Quattrocelli M; Barefield DY; Warner JL; Vo AH; Hadhazy M; Earley JU; Demonbreun AR; McNally EM
J Clin Invest; 2017 Jun; 127(6):2418-2432. PubMed ID: 28481224
[TBL] [Abstract][Full Text] [Related]
3. Effects of Glucocorticoids in Murine Models of Duchenne and Limb-Girdle Muscular Dystrophy.
Wintzinger M; Miz K; York A; Demonbreun AR; Molkentin JD; McNally EM; Quattrocelli M
Methods Mol Biol; 2023; 2587():467-478. PubMed ID: 36401044
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemistry of sarcolemmal membrane-associated proteins in formalin-fixed and paraffin-embedded skeletal muscle tissue: a promising tool for the diagnostic evaluation of common muscular dystrophies.
Suriyonplengsaeng C; Dejthevaporn C; Khongkhatithum C; Sanpapant S; Tubthong N; Pinpradap K; Srinark N; Waisayarat J
Diagn Pathol; 2017 Feb; 12(1):19. PubMed ID: 28219397
[TBL] [Abstract][Full Text] [Related]
5. An Open Label Exploratory Clinical Trial Evaluating Safety and Tolerability of Once-Weekly Prednisone in Becker and Limb-Girdle Muscular Dystrophy.
Zelikovich AS; Joslin BC; Casey P; McNally EM; Ajroud-Driss S
J Neuromuscul Dis; 2022; 9(2):275-287. PubMed ID: 35124660
[TBL] [Abstract][Full Text] [Related]
6. Aquaporin-4 expression is severely reduced in human sarcoglycanopathies and dysferlinopathies.
Assereto S; Mastrototaro M; Stringara S; Gazzerro E; Broda P; Nicchia GP; Svelto M; Bruno C; Nigro V; Lisanti MP; Frigeri A; Minetti C
Cell Cycle; 2008 Jul; 7(14):2199-207. PubMed ID: 18641458
[TBL] [Abstract][Full Text] [Related]
7. Glucocorticoid Steroid and Alendronate Treatment Alleviates Dystrophic Phenotype with Enhanced Functional Glycosylation of α-Dystroglycan in Mouse Model of Limb-Girdle Muscular Dystrophy with FKRPP448L Mutation.
Wu B; Shah SN; Lu P; Richardson SM; Bollinger LE; Blaeser A; Madden KL; Sun Y; Luckie TM; Cox MD; Sparks S; Harper AD; Lu QL
Am J Pathol; 2016 Jun; 186(6):1635-48. PubMed ID: 27109613
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms and Clinical Applications of Glucocorticoid Steroids in Muscular Dystrophy.
Quattrocelli M; Zelikovich AS; Salamone IM; Fischer JA; McNally EM
J Neuromuscul Dis; 2021; 8(1):39-52. PubMed ID: 33104035
[TBL] [Abstract][Full Text] [Related]
9. Myostatin blockade improves function but not histopathology in a murine model of limb-girdle muscular dystrophy 2C.
Bogdanovich S; McNally EM; Khurana TS
Muscle Nerve; 2008 Mar; 37(3):308-16. PubMed ID: 18041051
[TBL] [Abstract][Full Text] [Related]
10. Sarcoglycanopathies: can muscle immunoanalysis predict the genotype?
Klinge L; Dekomien G; Aboumousa A; Charlton R; Epplen JT; Barresi R; Bushby K; Straub V
Neuromuscul Disord; 2008 Dec; 18(12):934-41. PubMed ID: 18996010
[TBL] [Abstract][Full Text] [Related]
11. The effects of glucocorticoid therapy on the inflammatory and dendritic cells in muscular dystrophies.
Hussein MR; Hamed SA; Mostafa MG; Abu-Dief EE; Kamel NF; Kandil MR
Int J Exp Pathol; 2006 Dec; 87(6):451-61. PubMed ID: 17222213
[TBL] [Abstract][Full Text] [Related]
12. Epsilon-sarcoglycan compensates for lack of alpha-sarcoglycan in a mouse model of limb-girdle muscular dystrophy.
Imamura M; Mochizuki Y; Engvall E; Takeda S
Hum Mol Genet; 2005 Mar; 14(6):775-83. PubMed ID: 15689353
[TBL] [Abstract][Full Text] [Related]
13. Sarcolemmal proteins and the spectrum of limb-girdle muscular dystrophies.
Bönnemann CG; Finkel RS
Semin Pediatr Neurol; 2002 Jun; 9(2):81-99. PubMed ID: 12139001
[TBL] [Abstract][Full Text] [Related]
14. Limb-girdle muscular dystrophy.
Mathews KD; Moore SA
Curr Neurol Neurosci Rep; 2003 Jan; 3(1):78-85. PubMed ID: 12507416
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of sarcoglycans, vinculin-talin-integrin system and filamin2 in alpha- and gamma-sarcoglycanopathy: an immunohistochemical study.
Anastasi G; Cutroneo G; Trimarchi F; Santoro G; Bruschetta D; Bramanti P; Pisani A; Favaloro A
Int J Mol Med; 2004 Dec; 14(6):989-99. PubMed ID: 15547664
[TBL] [Abstract][Full Text] [Related]
16. Perturbation of muscle metabolism in patients with muscular dystrophy in early or acute phase of disease: In vitro, high resolution NMR spectroscopy based analysis.
Srivastava NK; Yadav R; Mukherjee S; Sinha N
Clin Chim Acta; 2018 Mar; 478():171-181. PubMed ID: 29278724
[TBL] [Abstract][Full Text] [Related]
17. Pulsed glucocorticoids enhance dystrophic muscle performance through epigenetic-metabolic reprogramming.
Quattrocelli M; Zelikovich AS; Jiang Z; Peek CB; Demonbreun AR; Kuntz NL; Barish GD; Haldar SM; Bass J; McNally EM
JCI Insight; 2019 Dec; 4(24):. PubMed ID: 31852847
[TBL] [Abstract][Full Text] [Related]
18. Autonomic, locomotor and cardiac abnormalities in a mouse model of muscular dystrophy: targeting the renin-angiotensin system.
Sabharwal R; Chapleau MW
Exp Physiol; 2014 Apr; 99(4):627-31. PubMed ID: 24334334
[TBL] [Abstract][Full Text] [Related]
19. Untangling the complexity of limb-girdle muscular dystrophies.
Liewluck T; Milone M
Muscle Nerve; 2018 Aug; 58(2):167-177. PubMed ID: 29350766
[TBL] [Abstract][Full Text] [Related]
20. Mutations in the delta-sarcoglycan gene are a rare cause of autosomal recessive limb-girdle muscular dystrophy (LGMD2).
Duggan DJ; Manchester D; Stears KP; Mathews DJ; Hart C; Hoffman EP
Neurogenetics; 1997 May; 1(1):49-58. PubMed ID: 10735275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
